Get started
Author

Kelly A. Conway

Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
2000 · Kelly A. Conway, Seung-Jae Lee, et al. · Proceedings of the National Academy of Sciences · 1,543
NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded
1996 · Paul H. Weinreb, Weiguo Zhen, et al. · Biochemistry · 1,524
Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
1998 · Kelly A. Conway, James D. Harper, et al. · Nature Medicine · 1,500
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
2001 · Kelly A. Conway, Jean-Christophe Rochet, et al. · Science · 1,127
Fibrils Formed in Vitro from α-Synuclein and Two Mutant Forms Linked to Parkinson's Disease are Typical Amyloid
2000 · Kelly A. Conway, James D. Harper, et al. · Biochemistry · 786
Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants
2000 · K. A. CONWAY, S.‐J LEE, et al. · Annals of the New York Academy of Sciences · 222
Inhibition of Fibrillization and Accumulation of Prefibrillar Oligomers in Mixtures of Human and Mouse α-Synuclein
2000 · Jean-Christophe Rochet, Kelly A. Conway, et al. · Biochemistry · 221
Interactions Among α-Synuclein, Dopamine, and Biomembranes: Some Clues for Understanding Neurodegeneration in Parkinson's Disease
2004 · Jean-Christophe Rochet, Tiago Fleming Outeiro, et al. · Journal of Molecular Neuroscience · 191
2-Amino-3,4-dihydroquinazolines as Inhibitors of BACE-1 (β-Site APP Cleaving Enzyme): Use of Structure Based Design to Convert a Micromolar Hit into a Nanomolar Lead
2007 · Ellen W. Baxter, Kelly A. Conway, et al. · Journal of Medicinal Chemistry · 146
Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
2003 · Kelly Conway, Ellen Baxter, et al. · Current Pharmaceutical Design · 40
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads
2010 · Yifang Huang, Eric D. Strobel, et al. · Bioorganic & Medicinal Chemistry Letters · 27
Synthesis of (−)-5,8-Dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: An Inhibitor of β-Amyloid1–42 Aggregation
2002 · Michael H Parker, Robert Chen, et al. · Bioorganic & Medicinal Chemistry · 25
Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation
2022 · Justin P. Wright, Jason R. Goodman, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 13
PDF
Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice
2018 · Andrew T. Templin, Daniel T. Meier, et al. · Diabetologia · 11
PDF
Virus-Based Expression Systems Facilitate Rapid Target In Vivo Functionality Validation and High-Throughput Screening
2003 · Andrew L. Darrow, Kelly A. Conway, et al. · SLAS DISCOVERY · 11
PDF
A Comparative Analysis of Brain and Plasma Aβ Levels in Eight Common Non-Transgenic Mouse Strains: Validation of a Specific Immunoassay for Total Rodent Aβ
2007 · George J. Yohrling, Kevin M. Felsenstein, et al. · Current Alzheimer Research · 10
Emerging β-Amyloid Therapies for the Treatment of Alzheimer's Disease
2004 · Kelly A. Conway, Ellen W. Baxter, et al. · Frontiers in Medicinal Chemistry - Online · 7
Ic‐p‐165: Studies to Evaluate the Putative Binding of the Tau Positron Emission Tomography Tracer 18f‐av‐1451 to Monoamine Oxidase‐b (mao‐b)
2019 · Justin P. Wright, Yin-Guo Lin, et al. · Alzheimer s & Dementia · 2
[o1–08–06]: an Update on the Binding Profile of Flortaucipir in Ad Versus Normal Cns Proteins and Normal Brain
2017 · Giorgio Attardo, Kelly Conway, et al. · Alzheimer s & Dementia · 1
P3‐071: Exploring AV1451 Binding Through Biochemical and Biophysical Analysis of PHF TAU From Human and TG4510 Brains with Electron Microscopy
2016 · Xiyun Chai, Kelly Conway, et al. · Alzheimer s & Dementia
PDF
Works count: 20
Citation count: 7,407
H-index: 13
I10-index: 16
Year
Topic
Type